(Total Views: 547)
Posted On: 09/30/2020 9:37:47 AM
Post# of 155304
Re: Rubraquercus #58526
Rubraquercus,
A new trial in long haulers will likely be needed. CD10 only 84 patients. Also, NEWS2 is the metric to track and predict clinical deterioration, so not the best way to track symptoms in long haulers.
Symptom resolution as well as immune imbalance (Incelldx assay) would be interesting.
Were it my trial, it would be three arms.
Placebo
Leronlimab
Corticosteroids.
I have not seen a trial design yet for long haulers. Has anyone else?
A new trial in long haulers will likely be needed. CD10 only 84 patients. Also, NEWS2 is the metric to track and predict clinical deterioration, so not the best way to track symptoms in long haulers.
Symptom resolution as well as immune imbalance (Incelldx assay) would be interesting.
Were it my trial, it would be three arms.
Placebo
Leronlimab
Corticosteroids.
I have not seen a trial design yet for long haulers. Has anyone else?
(1)
(0)
